Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31026276.
- Also identified by DOI 10.1371/journal.pcbi.1006878 and PMC identifier 6506148.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Drosophila provides an inexpensive and quantitative platform for measuring whole animal drug response. A complementary approach is virtual screening, where chemical libraries can be efficiently screened against protein target(s). Here, we present a unique discovery platform integrating structure-based modeling with Drosophila biology and organic synthesis. We demonstrate this platform by developing chemicals targeting a Drosophila model of Medullary Thyroid Cancer (MTC) characterized by a transformation network activated by oncogenic dRetM955T. Structural models for kinases relevant to MTC were generated for virtual screening to identify unique preliminary hits that suppressed dRetM955T-induced transformation. We then combined features from our hits with those of known inhibitors to create a 'hybrid' molecule with improved suppression of dRetM955T transformation. Our platform provides a framework to efficiently explore novel kinase inhibitors outside of explored inhibitor chemical space that are effective in inhibiting cancer networks while minimizing whole body toxicity.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Neuroendocrine
- Drug Evaluation, Preclinical
- Protein Kinase Inhibitors
- Protein Kinases
- Thyroid Neoplasms